Traders should monitor the AACR presentations for data depth, especially durability of immune response and biomarker correlation, which could influence sentiment. Participation in partnering events may lead to future collaboration announcements, potentially serving as a catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 18 $3.78entry
- T+1 · 8mo ago +5.82%α +6.09% · $4.00
- T+5 · 8mo ago −2.12%α −1.40% · $3.70
- T+20 · 7mo ago +9.52%α +3.48% · $4.14
- T+60 · 5mo ago −4.50%α −16.02% · $3.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced two abstracts accepted for presentation at the AACR Annual Meeting, featuring new biomarker and immunogenicity data for its personalized cancer vaccine EVX-01 in melanoma, and preclinical data on using its AI-Immunology™ platform to target glioblastoma. The company will also participate in an industry partnering event, signaling efforts to advance collaborations.
Key Facts
- Two abstracts accepted for AACR 2026 presentation: one on EVX-01 clinical data in advanced melanoma, another on AI-identified neoantigens for glioblastoma.
- EVX-01 data includes durable de novo T-cell responses from a Phase 2 trial combining the vaccine with KEYTRUDA® (pembrolizumab).
- Glioblastoma research is preclinical, focusing on endogenous retrovirus (ERV)-derived neoantigens identified via AI-Immunology™.
- Evaxion will attend the AACR Oncology Industry Partnering event, indicating business development activity.
Financial Impact
No financial impact disclosed; data is clinical and preclinical with no revenue or cost figures provided.
Risk Factors
- No efficacy or survival data (e.g., overall survival, progression-free survival) disclosed in the release.
- Glioblastoma program is preclinical; clinical applicability remains uncertain.
- EVX-01 remains in Phase 2; no guarantee of regulatory or commercial success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257673 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers